Browse
Prediction results retrieved after performance evaluation of WHO approved 34 primers to estimate their binding affinities for 3892 SARS-CoV-2 variants.

Lineage
(WHO label)
  
Target Gene
  
Primer Name
  
Primer Sequence
  
Primer Length
  
Primer GC Content (%)
  
Start Position
  
End Position
  
Primer Direction
  
ΔG (cal)
  
Primer first used
  
GE.1.1NUS-CDC-N-2GCGCGACATTCCGAAGAA1855.562923029213R-21404.2US
GE.1.1NYoung-NAGCACCATAGGGAAGTCC1855.562864828631R-19874.5Singapore
GE.1.1NChan-NGCGTTCTTCGGAATGTCG1855.562921029227F-21207.6China
EG.6.1NUS-CDC-N-2GCGCGACATTCCGAAGAA1855.562923029213R-21404.2US
EG.6.1NYoung-NAGCACCATAGGGAAGTCC1855.562864828631R-19874.5Singapore
EG.6.1NChan-NGCGTTCTTCGGAATGTCG1855.562921029227F-21207.6China
FU.2NUS-CDC-N-2GCGCGACATTCCGAAGAA1855.562923029213R-21404.2US
FU.2NYoung-NAGCACCATAGGGAAGTCC1855.562864828631R-19874.5Singapore
FU.2NChan-NGCGTTCTTCGGAATGTCG1855.562921029227F-21207.6China
DV.7.1NUS-CDC-N-2GCGCGACATTCCGAAGAA1855.562923029213R-21404.2US
DV.7.1NYoung-NAGCACCATAGGGAAGTCC1855.562864828631R-19874.5Singapore
DV.7.1NChan-NGCGTTCTTCGGAATGTCG1855.562921029227F-21207.6China
BA.2.86.2NUS-CDC-N-2GCGCGACATTCCGAAGAA1855.562923029213R-21404.2US
BA.2.86.2NYoung-NAGCACCATAGGGAAGTCC1855.562864828631R-19874.5Singapore
BA.2.86.2NChan-NGCGTTCTTCGGAATGTCG1855.562921029227F-21207.6China
HK.3.12NUS-CDC-N-2GCGCGACATTCCGAAGAA1855.562923029213R-21404.2US
HK.3.12NYoung-NAGCACCATAGGGAAGTCC1855.562864828631R-19874.5Singapore
HK.3.12NChan-NGCGTTCTTCGGAATGTCG1855.562921029227F-21207.6China
GN.1NUS-CDC-N-2GCGCGACATTCCGAAGAA1855.562923029213R-21404.2US
GN.1NYoung-NAGCACCATAGGGAAGTCC1855.562864828631R-19874.5Singapore
GN.1NChan-NGCGTTCTTCGGAATGTCG1855.562921029227F-21207.6China
JG.2NUS-CDC-N-2GCGCGACATTCCGAAGAA1855.562923029213R-21404.2US
JG.2NYoung-NAGCACCATAGGGAAGTCC1855.562864828631R-19874.5Singapore
JG.2NChan-NGCGTTCTTCGGAATGTCG1855.562921029227F-21207.6China
JD.1.2.2NUS-CDC-N-2GCGCGACATTCCGAAGAA1855.562923029213R-21404.2US
JD.1.2.2NYoung-NAGCACCATAGGGAAGTCC1855.562864828631R-19874.5Singapore
JD.1.2.2NChan-NGCGTTCTTCGGAATGTCG1855.562921029227F-21207.6China
JD.1.1.3NUS-CDC-N-2GCGCGACATTCCGAAGAA1855.562923029213R-21404.2US
JD.1.1.3NYoung-NAGCACCATAGGGAAGTCC1855.562864828631R-19874.5Singapore
JD.1.1.3NChan-NGCGTTCTTCGGAATGTCG1855.562921029227F-21207.6China
JR.1.1NUS-CDC-N-2GCGCGACATTCCGAAGAA1855.562923029213R-21404.2US
JR.1.1NYoung-NAGCACCATAGGGAAGTCC1855.562864828631R-19874.5Singapore
JR.1.1NChan-NGCGTTCTTCGGAATGTCG1855.562921029227F-21207.6China
GJ.1.2.6NUS-CDC-N-2GCGCGACATTCCGAAGAA1855.562923029213R-21404.2US
GJ.1.2.6NYoung-NAGCACCATAGGGAAGTCC1855.562864828631R-19874.5Singapore
GJ.1.2.6NChan-NGCGTTCTTCGGAATGTCG1855.562921029227F-21207.6China
JN.1.30NUS-CDC-N-2GCGCGACATTCCGAAGAA1855.562923029213R-21404.2US
JN.1.30NYoung-NAGCACCATAGGGAAGTCC1855.562864828631R-19874.5Singapore
JN.1.30NChan-NGCGTTCTTCGGAATGTCG1855.562921029227F-21207.6China
XDA.1NUS-CDC-N-2GCGCGACATTCCGAAGAA1855.562923029213R-21404.2US
XDA.1NYoung-NAGCACCATAGGGAAGTCC1855.562864828631R-19874.5Singapore
XDA.1NChan-NGCGTTCTTCGGAATGTCG1855.562921029227F-21207.6China
JN.1.58.3NUS-CDC-N-2GCGCGACATTCCGAAGAA1855.562923029213R-21404.2US
JN.1.58.3NYoung-NAGCACCATAGGGAAGTCC1855.562864828631R-19874.5Singapore
JN.1.58.3NChan-NGCGTTCTTCGGAATGTCG1855.562921029227F-21207.6China
XBB.1.5.33NUS-CDC-N-2GCGCGACATTCCGAAGAA1855.562923029213R-21404.2US
XBB.1.5.33NYoung-NAGCACCATAGGGAAGTCC1855.562864828631R-19874.5Singapore
XBB.1.5.33NChan-NGCGTTCTTCGGAATGTCG1855.562921029227F-21207.6China
JN.13.1NUS-CDC-N-2GCGCGACATTCCGAAGAA1855.562923029213R-21404.2US
JN.13.1NYoung-NAGCACCATAGGGAAGTCC1855.562864828631R-19874.5Singapore
Lineage
(WHO label)
  
Target Gene
  
Primer Name
  
Primer Sequence
  
Primer Length
  
Primer GC Content (%)
  
Start Position
  
End Position
  
Primer Direction
  
ΔG (cal)
  
Primer first used